Results 91 to 100 of about 3,194,118 (301)
Isaac Oludare Oluwayemi,1 Olusola Adetunji Oyedeji,2 Emmanuel Oluwatosin Adeniji,2 Adebukola Bidemi Ajite,1 Adefunke Olarinre Babatola,1 Adewuyi Temidayo Adeniyi,1,2 Ezra Olatunde Ogundare,1 Oladele Simeon Olatunya,1 Temitope Opeyemi Ayeni,3 Ayotunde ...
Oluwayemi IO +9 more
doaj
MITF maintains genome stability in nonmelanocyte lineages
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir +13 more
wiley +1 more source
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka +9 more
wiley +1 more source
Regulatory Opinion: Year in Review
As the new year arrives, The Regulatory Review would like to reflect on the many important regulatory developments that occurred in the United States and around the world during 2013.
The Regulatory Review
core
Tumor B‐cell infiltration in platinum‐treated advanced muscle‐invasive urothelial carcinoma
Bladder tumors with higher pretreatment memory B‐cell infiltration were linked to longer survival after cisplatin chemotherapy, but not carboplatin. These tumors also showed more organized immune structures (tertiary lymphoid structures) and a shared pro‐inflammatory B‐cell‐rich community, suggesting that memory B cells may help identify patients most ...
Konrad Stawiski +10 more
wiley +1 more source
The Year in Review for Renal Cancer
Ulka Vaishampayan, MD
doaj +1 more source
Liquid biopsy‐based diagnostic evaluation of hypermethylated CpG sites for ovarian cancer diagnosis
This schematic outlines the workflow from biomarker identification to duplex MethyLight assay validation for epithelial ovarian cancer diagnosis using cfDNA‐based liquid biopsy. Initial screening of hypermethylated CpG candidates (cg02957270, cg10061138 cg00480298, COL2A1) was performed in tissue using ARMS‐PCR, COBRA, qPCR and image analysis. Selected
Deepa Bisht +3 more
wiley +1 more source
Regulatory Analysis: Year in Review
As the new year arrives, The Regulatory Review would like to reflect on the many important regulatory developments that occurred in the United States and around the world during 2013.
The Regulatory Review
core
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi +11 more
wiley +1 more source

